According to the recent study the migraine drugs market is projected to reach an estimated $XX billion by 2028 from $XX billion in 2023, at a CAGR of 12% to 15% from 2023 to 2028. Growth in this market is primarily driven by growing cases of migraine due to stress, hormonal changes, and lifestyle diseases, increased uptake of novel drug classes, launch of calcitonin gene-related peptide (CGRP)-based therapies, and growing awareness programs regarding the prevention and treatment of migraine.
Browse XX figures / charts and XX tables in this 150 -page report to understand trends, opportunities and forecast in migraine drugs market by product type (acute migraine treatment and preventive migraine treatment), route of administration (oral, injectables, and others), distribution channel (hospital pharmacies, retail pharmacies and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World).
Download sample report by clicking on below link https://www.lucintel.com/migraine-drugs-market.aspx
“Acute migraine treatment market is expected to remain the largest segment during the forecast period.”
Based on product type, the migraine drugs market is segmented into acute migraine treatment and preventive migraine treatment. Lucintel forecasts that the acute migraine treatment market is expected to remain the largest segment due to ease of self-administration in case of patients with symptoms of nausea and vomiting along with migraine and growing utilization in combination with preventive treatments.
“Within the migraine drugs market, the online pharmacy segment is expected to remain the largest distribution channel”
Based on distribution channel the online pharmacy segment is expected to witness the highest growth over the forecast period due to because it provides migraine drugs through e-commerce platforms which is convenient, gives privacy of buying, hassel-free, and saves time by allowing people to refrain from waiting in queues. It is specifically helpful for individuals who live far from a regular pharmacy, the elderly, the crippled, and those who work extensively, this technique of receiving medication is both very simple and quick. In addition, the cost of delivery is far less than the expense of traveling to a regular pharmacy hence, provides additional benefit.
“Asia pacific will dominate the migraine drugs market in near future”
APAC will remain the fastest growing region due to rising prevalence of migraine in people due to increasing stress, work pressure, changing lifestyle, and consumption of alcohol, growing public awareness about the disease, rising healthcare spending, and accessibility to healthcare facilities.
Download Brochure of this report by clicking on https://www.lucintel.com/migraine-drugs-market.aspx
Major players of migraine drugs market are adopting various growth strategies like new product launches, expansions, merger and acquisitions, partnerships, agreements, and collaborations to expand their presence in this market. Allergan, Abbott Laboratories, AstraZeneca, Endo International, Eisai Co., Impax Laboratories, GlaxoSmithKline, Johnson Johnson, Pfizer Inc., Merck Co., and Sanofi SA are among the major migraine drugs providers.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link https://www.lucintel.com/migraine-drugs-market.aspx or helpdesk@lucintel.com
